ABSTRACT: Bupropion, a clinically used antidepressant and smokingcessation drug, acts as a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs). To identify its binding site(s) in nAChRs, we developed a photoreactive bupropion analogue, (±)-2-(N-tert-butylamino)-3′-[
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ABSTRACT: Bupropion, a clinically used antidepressant and smokingcessation drug, acts as a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs). To identify its binding site(s) in nAChRs, we developed a photoreactive bupropion analogue, (±)-2-(N-tert-butylamino)-3′-[ 125 I]-iodo-4′-azidopropiophenone (SADU-3-72). Based on inhibition of [
125 I]SADU-3-72 binding, SADU-3-72 binds with high affinity (IC 50 = 0.8 μM) to the Torpedo nAChR in the resting (closed channel) state and in the agonist-induced desensitized state, and bupropion binds to that site with 3-fold higher affinity in the desensitized (IC 50 = 1.2 μM) than in the resting state. Photolabeling of Torpedo nAChRs with [ 125 I]SADU-3-72 followed by limited in-gel digestion of nAChR subunits with endoproteinase Glu-C established the presence of [
125 I]SADU-3-72 photoincorporation within nAChR subunit fragments containing M1−M2−M3 helices (αV8-20K, βV8-22/23K, and γV8-24K) or M1−M2 helices (δV8-14). Photolabeling within βV8-22/23K, γV8-24K, and δV8-14 was reduced in the desensitized state and inhibited by ion channel blockers selective for the resting (tetracaine) or desensitized (thienycyclohexylpiperidine (TCP)) state, and this pharmacologically specific photolabeling was localized to the M2-9 leucine ring (δLeu 265 , βLeu 257 ) within the ion channel. In contrast, photolabeling within the αV8-20K was enhanced in the desensitized state and not inhibited by TCP but was inhibited by bupropion. This agonist-enhanced photolabeling was localized to αTyr 213 in αM1. These results establish the presence of two distinct bupropion binding sites within the Torpedo nAChR transmembrane domain: a high affinity site at the middle (M2-9) of the ion channel and a second site near the extracellular end of αM1 within a previously described halothane (general anesthetic) binding pocket.
(±)-Bupropion [(±)-2-(tert-butylamino)-1-(3-chlorophenyl) propan-1-one] (Figure 1 ) is an antidepressant agent (Wellbutrin) that is also effective in treating nicotine dependence (Zyban 1 ). While the consensus view is that bupropion's therapeutic efficacy as an antidepressant and a smoking cessation agent is attributable to its dual inhibition of dopamine and norepinephrine reuptake transporters, bupropion is also a noncompetitive antagonist (NCA) of several nicotinic acetylcholine receptors (nAChRs 2−4 ). There is emerging evidence that inhibition of neuronal nAChRs, in particular α4β2 and α3β4 subtypes, may contribute to the therapeutic benefit of bupropion as a smoking cessation agent (reviewed in ref 5) . nAChRs are members of the Cys-loop ligand-gated ion channel superfamily, which also includes γ-aminobutyric acid type A (GABA A ) receptors, 5-hydroxytryptamine type 3 (5-HT 3 ) receptors, glycine receptors found in vertebrates, and additional ligand-gated receptors found in invertebrates (reviewed in refs 6 and 7). Based on the three-dimensional structure of the Torpedo nAChR 8 and the available structural information regarding neuronal nAChRs (reviewed in refs 9 and 10), nAChRs are pentameric membrane proteins formed by the assembly of homologous subunits, which for the Torpedo nAChR has a subunit stoichiometry of 2α1β1γδ. Each nAChR subunit contains a large extracellular N-terminus and a bundle of four transmembrane α-helices (M1−M4). The five M2 helices are arranged about a central axis orthogonal to the membrane forming the channel lumen and the M1, M3, and M4 helices form an outer ring that shield M2 from the lipid bilayer.
Pharmacological studies have shown that bupropion and its analogues noncompetitively inhibit both muscle-type (fetal human α1β1γδ and Torpedo) and neuronal (α4β2, α3β4, α7) nAChRs in the low to intermediate micromolar range (IC 50 values range from 0.4 to 60 μM), with a rank order of potency: α3 → α1−α4 → α7-containing nAChRs. 4, 5 From an analysis of bupropion effects on agonist-induced macroscopic currents for α1β1εδ (adult mouse muscle type) nAChRs expressed in HEK-293 cells, it was concluded that bupropion inhibits the receptor via two mechanisms mediated by binding to specific conformational states. Bupropion binding to the resting nAChR results in impaired channel opening (IC 50 0.4 μM), while binding to the open state results in either slow channel block or an increase in the rate of desensitization. 11 Radioligand competition binding experiments to Torpedo nAChRs further established that bupropion binds to the desensitized state with ∼2-fold greater affinity than to the resting (closed) state. 11 While molecular docking and dynamics simulations predict that bupropion binds near the middle of the nAChR ion channel (between M2-6 and M2-13 11 ), there has been no direct experimental identification of bupropion binding sites in any nAChR subtype.
To Preparation of Affinity-Purified Torpedo nAChR Membrane Vesicles. Torpedo californica nAChR-rich membranes for radioligand binding studies and for affinity-purification were isolated from frozen electric organs as described previously.
14 Torpedo nAChR-rich membranes at 1 mg protein/ mL were solubilized in 1% sodium cholate in vesicle dialysis buffer (VDB, 100 mM NaCl, 0.1 mM EDTA, 0.02% NaN 3 , 10 mM MOPS, pH 7.5) and treated with 0.1 mM diisopropylfluorophosphate after insoluble material was pelleted by centrifugation (91000g for 1 h). The nAChR was affinitypurified on a bromoacetylcholine bromide-derivatized Affi-Gel 10 column and then reconstituted into lipid vesicles composed of dioleoylphosphatidylcholine, dioleoylphosphatidic acid, and cholesterol (DOPC:DOPA:CH at a molar ratio of 3:1:1), as described. 15, 16 The lipid to nAChR ratio was adjusted to a molar ratio of 400:1. After purification, the nAChR comprised more than 90% of the protein in the preparation based upon SDS-PAGE. Both the nAChR-rich membranes and purified nAChRs were stored at −80°C.
Electrophysiological Recordings. Voltage clamp electrophysiological studies were conducted using preassembled Torpedo nAChRs incorporated into the plasma membrane of Xenopus oocytes. 17, 18 Affinity-purified Torpedo nAChRs reconstituted in DOPC/DOPA/CH (3:1:1 molar ratio) lipid vesicles were microinjected into oocytes (50 nL at 2.5 mg/mL protein). Following an incubation period (48 h) to allow nAChR vesicles to fuse with the plasma membrane, current recordings were performed at room temperature. Currents were recorded from individual oocytes under two-electrode voltage clamp conditions at a holding potential of −60 mV. The ground electrode was connected to the bath via a 3 M KCl/agar bridge. Glass microelectrodes had a resistance of <2 MΩ when filled with 3 M KCl. Data were acquired and analyzed using a TEV-200 amplifier (Dagan Instruments, Minneapolis, MN), a Digidata 1440A data interface (Molecular Devices, Sunnyvale, CA), and pClamp 10.2 software (Molecular Devices). The concentatration dependence of bupropion inhibition was fit using a variable-slope sigmoidal dose response curve in Prism v5.00 (GraphPad Software, La Jolla, CA). Error bars indicate SEM acetylcholine (ACh) and bupropion were prepared as 1 M and 20 mM stock solutions, respectively, in distilled water. All solutions were made fresh from stock on the day of the experiment.
[ 125 I]-SADU-3-72 (∼2100 Ci/mmol) in the presence of 5 μM α-BgTx or 400 μM Carb for 1 h at room temperature under reduced light conditions. The samples were irradiated with a 365 nm hand-held UV lamp (Spectroline EN-280 L) for 10 min at a distance of less than 1 cm and then pelleted by centrifugation (39000g for 1 h at 4°C). Pellets were resuspended in electrophoresis sample buffer (12.5 mM Tris-HCl, 2% SDS, 8% sucrose, 1% glycerol, 0.01% bromophenol blue, pH 6.8), and the polypeptides were resolved by SDS-PAGE.
In some experiments, the NCAs tetracaine (130 μM) or thienylcyclohexylpiperidine (TCP; 130 μM) were added to Torpedo nAChR samples incubated with [
125 I]-SADU-3-72 in the presence of α-BgTx or Carb, respectively. Tetracaine binds in the Torpedo nAChR channel with 30-fold higher affinity in the resting than in the desensitized state, with an established binding locus in the closed channel. 20 Reciprocally, TCP, a close structural analogue of phencyclidine (PCP), binds to desensitized Torpedo AChR with higher affinity and with nearly identical affinity as PCP, which has an established binding locus in the ion channel in the desensitized state. 21 Torpedo nAChR samples were incubated with SDS−Polyacrylamide Gel Electrophoresis. SDS-PAGE was performed according to ref 22 with separating gels comprised of 8% polyacrylamide/0.33% bis(acrylamide) (1 mm thick gels for analytical labelings; 1.5 mm thick gels for preparative labeling experiments). Following electrophoresis, gels were stained for 1 h with Coomassie Blue R-250 (0.25% (w/v) in 45% methanol, 10% acetic acid, 45% H 2 O) and destained (25% methanol, 10% acetic acid, 65% H 2 O) to visualize bands. Gels were then dried and exposed to Kodak X-OMAT LS film with an intensifying screen at −80°C (5−24 h exposure). After autoradiography, the bands corresponding to the [ 125 I]-SADU-3-72-labeled nAChR subunits were excised from each condition, soaked in overlay buffer (5% sucrose, 125 mM Tris-HCl, 0.1% SDS, pH 6.8) for 30 min, and transferred to the wells of a 15% acrylamide "mapping" gel. 23 Each gel slice was overlaid with 5 μg (analytical labeling) or 100 μg (preparative labeling) of S. aureus V8 protease in overlay buffer. After electrophoresis, the gels were stained for 1 h with Coomassie Blue R-250, destained, and either prepared for autoradiography (analytical labeling) or soaked in distilled water overnight (preparative labeling). The 125 I-containing bands were excised from the preparative gels, and the peptides were retrieved by passive diffusion into 25 mL of elution buffer (0.1 M NH 4 HCO 3 , 0.1% (w/v) SDS, 1% β-mercaptoethanol, pH 7.8) for 4 days at of ACh, responses were measured when ACh was applied simultaneously for 20 s with increasing concentrations of bupropion (0.03−100 μM), and in each case a representative current trace is displayed. Inhibition by bupropion was reversible since peak responses to ACh returned to control levels after exposure to 3 μM bupropion followed by a 6 min wash (not shown). (B) Nonlinear least-squares analysis of the curves yielded an IC 50 = 0.34 ± 0.07 μM and nH = 0.98 ± 0.14 (7 oocytes). Currents were normalized to the 50 μM ACh response. room temperature with gentle mixing. The eluates were filtered to remove gel pieces and then concentrated using Centriprep-10 concentrators (10 kDa cutoff, Amicon, final volume <150 μL). Samples were then either directly purified by reversed-phase HPLC or acetone precipitated (>85% acetone at −20°C overnight) to remove excess SDS and then subjected to further proteolytic digestion.
Proteolytic Digestions and Tricine SDS-PAGE. For digestion with trypsin, acetone-precipitated subunit fragments were suspended in 30 μL of 0.1 M NH 4 HCO 3 , 0.1% SDS, pH 7.8, and then the SDS content was diluted by addition of 113 μL of 0.1 M NH 4 HCO 3 and 7.5 μL of Genapol C-100 (final concentrations: 0.02% (w/v) SDS, 0.5% Genapol C-100, pH 7.8). Trypsin (60 μg) was added, and the digestion was allowed to proceed for 5 days at room temperature.
Material from each digest was then resolved on 1.0 mm thick small pore (16.5% T/6% C) Tricine SDS-PAGE gels. 24, 25 After Coomassie Blue R-250 staining (1 h) and destaining (3−4 h), Tricine gels were dried and exposed to film (8−12 h). The 125 Icontaining bands were excised from the Tricine gels and subjected to reversed-phase HPLC purification as indicated in the previous section.
Reversed-Phase HPLC Purification. HPLC was performed on a Shimadzu LC-10A binary HPLC system using a Brownlee Aquapore C 4 column (100 × 2.1 mm). Solvent A was comprised of 0.08% trifluoroacetic acid (TFA) in water, and solvent B was comprised of 0.05% TFA in 60% acetonitrile/ 40% 2-propanol. A nonlinear elution gradient at 0.2 mL/min was employed (25−100% solvent B in 100 min, shown as a dotted line in the figures), and fractions were collected every 2.5 min (42 fractions/run). The elution of peptides was monitored by the absorbance at 210 nm, and the amount of 125 I associated with each fraction was determined by γ-counting (5 min/fraction) in a Packard Cobra II γ-counter.
Sequence Analysis. Amino terminal sequence analysis of Torpedo nAChR subunit fragments was performed on a Applied Biosystems PROCISE 492 protein sequencer configured to utilize 1/6 of each cycle of Edman degradation for amino acid identification/quantification and collect the other 5/6 for 125 I counting. The pooled HPLC fractions were diluted 3-fold with 0.1% TFA in distilled water (to reduce organic concentration) and loaded onto PVDF disks using Prosorb sample preparation cartridges (Applied Biosystems No. 401950). Before sequencing, filters were processed as recommended by the manufacturer. To determine the amount of the sequenced peptide, the pmol of each amino acid in a detected sequence was quantified by peak height and fit to the equation f(x) = I 0 R x , where I 0 was the initial amount of the peptide sequenced (in pmol), R was the repetitive yield, and f(x) was the pmol detected in cycle x. Ser, His, Trp, and Cys were not included in the fits due to known problems with their accurate detection/ quantification. The fit was calculated in SigmaPlot 11 (SPSS) using a nonlinear least-squares method, and figures containing 125 I release profiles ( Figures 6C,D Maximum acetylcholine (ACh) induced currents were obtained ∼48 h after nAChR microinjection, and the ACh dose− response curve yielded values (EC 50 = 50 μM; Hill coefficient, nH = 1.5; n = 1) consistent with previously published data. 18 Coapplication of bupropion resulted in a dose-dependent and reversible reduction in ACh-induced currents ( Figure 2 ) with an IC 50 = 0.34 ± 0.07 μM and nH = 0.98 ± 0.14 (n = 7). Thus, [ 125 I]SADU-3-72 Photolabeling of the Torpedo nAChR. In initial photolabeling experiments we characterized photoincorporation into the Torpedo nAChR in the resting state (stabilized by α-BgTx 19 ) and in the desensitized state (stabilized by Carb), and we examined the effect of tetracaine or TCP on the extent of photolabeling. Torpedo nAChR-rich membranes or purified nAChR in lipid vesicles were photolabeled with [
125 I]SADU-3-72 (1.5 nM); after UV-irradiation, nAChR subunits were separated by SDS-PAGE, and photolabeling was monitored by autoradiography ( Figure 4A ) and by γ-counting of excised subunit bands ( Figure 4B) . A representative autoradiograph of an SDS-PAGE gel of [
125 I]SADU-3-72-labeled native nAChR ( Figure 4A ) demonstrates photoincorporation into each nAChR subunit. In the nAChR resting state (+α-BgTx), tetracaine reduced photolabeling in the β-, γ-, and δ-subunits by 55, 51, and 73%, respectively, but by <5% in the α-subunit. Compared to the nAChR resting state, [
125 I]SADU-3-72 photolabeling in the desensitized state (Carb +) was unchanged in the α-subunit but was reduced by 50−70% in the β-, γ-, and δ-subunits. In the nAChR desensitized state, TCP inhibited [
125 I]SADU-3-72 photolabeling in the γ-and δ-subunits by ∼35%, while photolabeling in the α-subunit was increased by ∼15%, and β-subunit labeling was unchanged. As a control, no reproducible effect on the extent of [
125 I]SADU-3-72 photolabeling of the α-subunit of the Na,K-ATPase (αNK band) was observed between any of the different labeling conditions (data not shown). Qualitatively and quantitatively similar results for nAChR labeling were observed for [
125 I]SADU-3-72 photolabeling experiments conducted with purified Torpedo nAChRs (data not shown).
Bupropion also inhibited [ 125 I]SADU-3-72 photolabeling in a concentration-dependent manner, as determined by the level of subunit photolabeling determined by SDS-PAGE. The concentration dependence of bupropion inhibition of δ subunit photolabeling in the absence (IC 50 , 5.5 ± 0.7 μM) and presence of Carb (IC 50 , 2.1 ± 0.7 μM) (Supporting Information Figure  S1 ) was similar to that seen for the inhibition of reversible [
125 I]SADU-3-72 binding ( Figure 3B ). To further localize the site(s) of [ 125 I]SADU-3-72 labeling within each nAChR subunit, we employed limited digestion with S. aureus V8 protease in a 15% acrylamide mapping gel. 23 Limited V8 digestion reproducibly generates a set of nonoverlapping fragments for each receptor subunit 25,27−29 including fragments of ∼20 kDa containing the M1, M2, and M3 helices (αV8-20K, βV8-22/23K, γV8-24K) or of 14 kDa containing the M1 and M2 helices (δV8-14K), and fragments of 10−14 kDa containing the M4 helix (αV8-10K, βV8-12K, and γV8-14K).
Inspection of the autoradiograph of the V8 protease digests ( Figure 5A ,B) and γ counting of the excised gel bands ( Figure 5C ) revealed that for nAChR in the resting state tetracaine inhibited [
125 I]SADU-3−72 labeling within the αV8-20K, βV8-22/23K, γV8-24K, and δV8-14K fragments by 49, 76, 79, and 88%, respectively, which is likely to result from photolabeling in each subunit in the M2 ion channel domain. Compared to the resting state, for the nAChR desensitized state photolabeling in the βV8-22/23K, γV8-24K, and δV8-14K fragments was reduced by 60, 45, and 75%, and TCP further inhibited labeling in each of these fragments. The TCP-inhibitable [ 125 I]SADU-3-72 labeling within βV8-22/23K, γV8-24K, and δV8-14K predicts photolabeling of amino acids within these M2 segments, In contrast, there was an ∼2-fold increase in photolabeling within αV8-20K in the desensitized compared to resting state. This agonist-enhanced photolabeling within αV8-20K was not inhibited by TCP, but bupropion did reduce the photolabeling by 70% ( Figure 5C ). In each subunit there was also [
125 I]SADU-3-72 labeling that was neither affected by agonist (Carb) nor inclusion of tetracaine or TCP and that mapped to the αV8-10K, βV8-12K, βV-8K, and γV8-14K subunit fragments that contain the M4 helices.
[ 125 I]SADU-3-72 Photolabeling in the M2 Ion Channel Domain. For the Torpedo nAChR in the resting state, the principal site of tetracaine-inhibitable labeling resides within δV8-14K and βV8-22/23K ( Figure 5 ). To identify the photolabeled amino acids, δV8-14 and βV8-22/23 fragments, isolated from Torpedo nAChRs labeled with [
125 I]SADU-3-72 in the presence of α-BgTx or Carb, were further digested with trypsin, and the digests were separated by Tricine SDS-PAGE (Supporting Information, Figure S2 , panels B and C). The principal labeled fragments (δT-5K and βT-7K) isolated from the gel were further purified by reversed-phase HPLC ( Figure  6A,B) , and peak 125 I cpm fractions were subjected to amino acid sequence analysis ( Figure 6C,D) . Sequencing revealed in each case the presence of a primary peptide beginning at the start of the M2 segment (δMet 257 and βMet 249 ) and that [
125 I]SADU-3-72-labeled homologous leucine residues (δLeu 265 , 30 cpm/pmol; βLeu 257 , 5 cpm/pmol) located nine residues from the start of the M2 segment (M2−9).
Photolabeling of βM2-9 and δM2-9 was reduced by >90% in the desensitized compared to resting state, despite the fact [
125 I]SADU-3-72 binds with similar affinity to the nAChR in both states ( Figure 3A ). There was, however, TCP-inhibitable photolabeling in δV8-14K and βV8-22/23K ( Figure 5 ). To determine whether [ the resting state, and photolabeling was inhibited by bupropion but not by the channel blocker TCP ( Figure 5C ). To further localize this Carb-enhanced, bupropion-inhibitable labeling, the αV8−20K fragments isolated from Torpedo nAChRs labeled with [
125 I]SADU-3-72 in the absence and presence of Carb were digested with trypsin, the digests separated by Tricine SDS-PAGE gel (Supporting Information, Figure S2, panel A) . The principal photolabeled fragment (αT-5K) was isolated and purified by reversed-phase HPLC ( Figure 8A ). Amino acid sequence analysis ( Figure 8B ) revealed a primary peptide beginning at αIle 210 at the NH 2 -terminus of the αM1 segment. The major peak of 125 I release in cycle 4 indicated photolabeling of αTyr 213 , with labeling of this residue ∼10-fold greater in the desensitized vs resting Torpedo nAChR (10 and 1 cpm/pmol, respectively). In addition, there was a small peak of 125 I release in cycle 13, consistent with [
125 I]SADU-3-72 labeling of αCys 222 at similar efficiency in the resting and desensitized states (2 cpm/pmol).
[ 125 I]SADU-3-72 Photolabeling in αM4. Approximately 80% of the total [
125 I]SADU-3-72 photoincorporation into the α-subunit resides within the proteolytic fragment αV8-10 (Asn 339 -Gly 437 , Figure 5 ) with that photolabeling unaltered by inclusion of agonist or channel blockers (TCP, tetracaine). To identify the photolabeled amino acids, αV8-10K fragments, isolated from Torpedo nAChRs labeled with [
125 I]SADU-3-72 in the absence and presence of Carb, were digested with trypsin. When the digests were fractionated by reversed-phase HPLC (Supporting Information Figure S3A ), all 125 I was recovered in a broad hydrophobic peak, which amino acid sequence analysis (Supporting Information Figure S3B While inhibition of presynaptic dopamine and norepinephrine transporters is believed to be the primary mechanism underlying bupropion's efficacy, there is emerging evidence that inhibition of neuronal nAChRs also contributes to its efficacy in treating nicotine dependence (reviewed in refs 4 and 5). Bupropion inhibits noncompetitively a diverse group of muscle and neuronal nAChR subtypes, 4,5 with a predicted binding site within the receptor's ion channel. 11 A novel photoreactive analogue of bupropion, (±)-2-(N-tert-butylamino)-3′-[
125 I]-iodo-4′-azidopropiophenone ([ 125 I]-SADU-3-72), has been recently developed that photoincorporates into dopamine transporters and nAChRs. 12 In this report we used For Torpedo nAChRs injected into Xenopus oocytes, we found that bupropion inhibits reversibly ACh-induced currents with an IC 50 of 0.3 μM, similar to the reported IC 50 for bupropion inhibition of mouse muscle-type nAChR. 11 We also established that bupropion inhibits the reversible binding and UV-induced photoincorporation of [
125 I]-SADU-3-72 into the Torpedo nAChR with high affinity in the desensitized state (IC 50 's of 1 and 2 μM), as expected for mutually exclusive binding at a 125 I]-SADU-3-72 photolabeling within γV8-24 and δV8-14, but not within αV8-20, where there was agonistenhanced photolabeling that was inhibitable by bupropion. These results indicate the presence of at least two binding sites for [
125 I]-SADU-3-72/bupropion in the nAChR in the desensitized state: a site within the ion channel that is inhibitable by TCP and a second site, inhibitable by bupropion, that is in proximity to amino acid(s) within αM1/ α M2/and/ or αM3. 
, in proximity to amino acids from the γ-and/ or β-subunits, identified by the photolabeling in the desensitized state of αTyr 213 near the extracellular end of αM1; (iii) at the lipid interface, identified by the photolabeling of αCys 412 and αCys 418 in αM4 at similar efficiency in the resting and desensitized states. αCys 412 and αCys 418 , and others lying on a common strip of the αM4 helix, have been photolabeled by a variety of hydrophobic probes of diverse structure and photoreactivity that partition into lipid. 25, 27, 31, 32 [ 125 I]-SADU-3-72/Bupropion Binding in the Ion Channel.
[
125 I]-SADU-3-72 photolabeled βM2-9 and δM2-9 within the ion channel at >10-fold higher efficiency in the resting state than in the desensitized state, despite the fact that [
125 I]-SADU-3-72 binds with similar high affinity (∼1 μM) in both states ( Figure 3A) , as does bupropion. 11 In this regard, [ 125 I]-SADU-3-72 mirrors [
125 I]TID, a NCA that binds in the nAChR ion channel with similar high affinity in the desensitized and resting states but photolabels amino acids in the nAChR ion channel with ∼10-fold higher efficiency in the resting state than in the desensitized state. 33, 34 By photolabeling nAChRs in the desensitized state at a higher concentration of [
125 I]SADU-3-72, we also identified photolabeling of δLeu 265 (M2-9), inhibitable by TCP, and δSer 258 (M2-2). This indicates that 13 and amino acid substitutions at this position perturb gating, with the accessibility of αTyr 213 Cys-substituted receptors to chemical modification increased by agonist. 35, 36 Thus, αTyr 213 contributes to a water-accessible, general anesthetic binding pocket located at the same interface between subunits where uncharged positive and negative nAChR allosteric modulators bind more toward the middle of the transmembrane domain. 37, 38 The agonist-enhanced photolabeling of αTyr 213 may be explained by the formation of SADU-3-72-accessible pocket in the vicinity of αTyr 213 during desensitization, but further studies are required to examine the presence of this pocket and its accessibility to SADU- 3- Conclusions and Implications. In this report, we provide a direct identification, at the amino acid level, of two distinct 125 I]-SADU-3-72 in the Torpedo δ-and β-subunits are conserved in all nAChRs (as well as across the Cys loop receptor family), it is tempting to predict a common bupropion binding site at M2-9 in the ion channel in all nAChR subtypes. However, given the range of bupropion potencies for inhibition of diverse nAChR subtypes, 5 such an extrapolation could be an oversimplification, and the molecular determinants of bupropion binding to different nAChR ion channels may be subtypespecific. Moreover, it remains to be determined whether or not an equivalent bupropion binding site at αTyr 213 is present in neuronal nAChRs. 
